Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05410418 · ClinicalTrials.gov registry record · Phase 2
Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
A Phase 2 study of Follicular Lymphoma and Lymphoma, Follicular, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT05410418 is a Phase 2 study of Follicular Lymphoma and Lymphoma, Follicular that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 34 participants, below the 135-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05410418, a Phase 2 study of Follicular Lymphoma and Lymphoma, Follicular, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II clinical trial studies the combination of mosunetuzumab and polatuzumab vedotin in order to see how well it works in patients with untreated follicular lymphoma. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in the immune system: T cells that normally perform tasks like killing virus-infected cells, and cancerous B cells. Mosunetuzumab has been designed to direct these T cells to kill the cancerous B cells instead. Polatuzumab vedotin is an antibody-drug conjugate that attaches to certain cancerous B cells and then delivers a drug specifically to those cells.
Conditions Studied
Interventions
- DRUG Mosunetuzumab
- DRUG Polatuzumab vedotin
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2022-10-24 |
| Est. Completion | 2029-04-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05410418
The ClinicalTrials.gov registry entry for NCT05410418 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (75% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Follicular Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Mosunetuzumab is the first listed.
NCT05410418 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT05410418 about?
NCT05410418 is a clinical study titled "Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma". This phase II clinical trial studies the combination of mosunetuzumab and polatuzumab vedotin in order to see how well it works in patients with untreated follicular lymphoma. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in the immune system: T cells that norma...
What is the current status of trial NCT05410418?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2022-10-24. Estimated completion is 2029-04-24.
What conditions does trial NCT05410418 study?
This clinical trial studies the following conditions: Follicular Lymphoma, Lymphoma, Follicular.
What interventions are being tested in trial NCT05410418?
The interventions under investigation include: Mosunetuzumab (DRUG), Polatuzumab vedotin (DRUG).
Who is sponsoring clinical trial NCT05410418?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05410418 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
RECRUITING · Phase 2
-
Epcoritamab and Rituximab for First-line Follicular Lymphoma
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.